Avadel reports Q1 LUMRYZ revenue $27.2M; patient starts up 70%; pediatric sNDA accepted

AVADEL PHARMACEUTICALS PLC

2024-Q1 EPS reported -$0.30 revenue$27,178,000

Q1 2024 net product revenue of $27.2M from LUMRYZ; gross profit $25.7M.
Net loss narrowed to $27.3M ($0.30 per share) vs. $30.8M ($0.48) in Q1 2023.
Over 1,700 patients initiated therapy (up >70% from Dec 31); RYZUP enrollments 2,800 (up ~50%).
FDA accepted sNDA for LUMRYZ in pediatric narcolepsy; PDUFA date set for Sept 7, 2024.
On track to enroll first patient in Phase 3 idiopathic hypersomnia trial in H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AVADEL PHARMACEUTICALS PLC reported the quarter ended March 31, 2024 results: revenue $27.2 million, net income $27.3 million, EPS ($0.30) per diluted share.

Period: the quarter ended March 31, 2024
Revenue: $27.2 million
Net income: $27.3 million
EPS: ($0.30) per diluted share
Result: reported results

Exact text from the filing

--- EX-99.1 2 tm2413641d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results -- Generated $27.2 million in net revenue from sales of LUMRYZTM -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-058415

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.